Kalaris Therapeutics, Inc. (KLRS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $10.56
• Market Cap: $198.81M
• EPS: $-38.05
• 52-Week High: $12.90
• 52-Week Low: $2.14

Market Sentiment

Kalaris Therapeutics, Inc. currently has a Bullish sentiment score of 0.24.

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Palo Alto, California, dedicated to developing innovative therapies for neovascular retinal diseases, thereby addressing critical unmet medical needs in ocular health. The firm harnesses advanced research and development capabilities to create transformative treatments aimed at improving patient outcomes. With a strong pipeline and a team of seasoned professionals, Kalaris is well-positioned to make signific...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Kalaris Therapeutics, Inc. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KLRS pay dividends?

Kalaris Therapeutics, Inc. (KLRS) does not currently pay a regular dividend.

What is KLRS's market cap?

Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $198.81M with a current stock price of $10.56.